Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 26 2019 - 8:32AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by complement-mediated diseases,
today announced that Joseph Truitt, President and Chief Executive
Officer of Achillion will present at the 2019 Cantor Fitzgerald
Global Healthcare Conference on Thursday, October 3, 2019, at 8:55
a.m. ET at the InterContinental New York Barclay in New York, NY.
The live audio and subsequent archived webcasts
of the Company's presentation will be accessible from the Company's
investor relations website, http://ir.achillion.com. The audio
recording will be archived for 60 days following the live
presentation. Please connect to Achillion's website several minutes
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary.
About Achillion
Pharmaceuticals Achillion Pharmaceuticals, Inc.
(Nasdaq: ACHN) is a clinical-stage biopharmaceutical company
focused on advancing its oral small molecule complement inhibitors
into late-stage development and commercialization. Research has
shown that an overactive complement system plays a critical role in
multiple disease conditions including the therapeutic areas of
nephrology, hematology, ophthalmology and neurology. Achillion is
initially focusing its drug development activities on
complement-mediated diseases where there are no approved therapies
or where existing therapies are inadequate for patients. Potential
indications being evaluated for its compounds include paroxysmal
nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune
complex membranoproliferative glomerulonephritis (IC-MPGN). The
company has received Breakthrough Therapy designation for danicopan
for treatment in combination with a C5 monoclonal antibody for
patients with paroxysmal nocturnal hemoglobinuria (PNH) who are
sub-optimal responders to a C5 inhibitor alone. Each of the
product candidates in the Company’s oral small molecule portfolio
was discovered in its laboratories and is wholly owned. To advance
its investigational product candidates into Phase 3 clinical trials
and commercialization, the Company plans to work closely with key
stakeholders including healthcare professionals, patients,
regulators and payors.
More information is available at
http://www.achillion.com
Investor Relations: A.
Clayton Robertson Achillion Pharmaceuticals, Inc. Tel. (215)
709-3078 crobertson@achillion.com
Media: Susanne Heinzinger
Senior VP, Corporate Communications Achillion Pharmaceuticals, Inc.
Tel. (215)709-3032 sheinzinger@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024